Loading clinical trials...

Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis

Improvement of Atopic Dermatitis Symptoms and Signs by Jelly Fig (Ficus Awkeotsang Makino) Extract

NCT07113366•Kaohsiung Veterans General Hospital.

Summary

The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis. Ficus awkeotsang is a traditional plant native to Taiwan.

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥12 years at the time of enrollment
•Clinical diagnosis of atopic dermatitis (AD) according to the Hanifin and Rajka criteria
•Investigator's Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at screening

Exclusion Criteria

•Prior treatment with biologic agents within 16 weeks before baseline
•Use of phototherapy, systemic corticosteroids, or other systemic immunosuppressants within 28 days before baseline
•Use of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 14 days before baseline
•Presence of active skin infections
•Pregnancy or breastfeeding
•Known hypersensitivity to any component of the investigational product

Locations (1)

Kaohsiung Veterans General Hospital

Kaohsiung City, Kaohsiung, Taiwan

Key Dates

Start Date

May 1, 2024

Primary Completion Date

June 1, 2024

Completion Date

November 30, 2024

Last Updated

August 8, 2025

Enrollment

ACTUAL participants

Conditions

Atopic Dermatitis (AD)

Interventions

FAE cream

DRUG

Placebo

DRUG

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395

Atopic Dermatitis (AD)

View study

RECRUITINGPHASE1

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

NCT07235384

Atopic Dermatitis (AD)

View study

RECRUITINGNA

Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis

Inclusion Criteria

Exclusion Criteria

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population

Herbal Ointment in Treating Atopic Dermatitis Topically

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis